New Guidelines for Myelofibrosis Care Emphasize Genetic Testing and Early Referrals

The American Society of Hematology (ASH) has issued new guidelines to improve the management of myelofibrosis, a rare and aggressive blood cancer. The recommendations focus on advancing diagnostic approaches and optimizing treatment strategies for patients.

Experts now advise broader use of molecular testing to identify genetic mutations that influence disease progression. This allows for more personalized treatment plans tailored to individual patient profiles.

The guidelines also highlight the importance of referring eligible patients to bone marrow transplant specialists earlier in their care journey. Early evaluation for transplants may improve long-term survival rates in certain cases.

Additional recommendations include careful consideration of JAK inhibitor medications and aspirin therapy for specific patient groups, based on current evidence about their benefits and risks.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.